Feasibility and Reproducibility of T1 Rho MRI in the Evaluation of Hip Cartilage (CARHAT02)

May 20, 2026 updated by: Hospices Civils de Lyon
Hip osteoarthritis is a frequent and invalidating disease. Early detection of cartilage modifications could provide better patient treatment. The T1rho MRI sequence allows the quantification of the cartilage signal that is correlated to modifications of the cartilage matrix, notably of the proteoglycans. The primary objective is to evaluate normal values of hip cartilage in vivo using T1rho MRI in healthy subjects and the reproducibility of the measurements. T1rho and T2 mapping sequences were acquired twice during the same session with 30 minutes interval to see if values were modified after a 30 minutes delay in a supine position. The secondary objective was to assess the correlation between T1rho and T2 values.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lyon, France, 69437
        • Hospices Civils de Lyon - Hôpital Edouard Herriot Pavillon B Radiologie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 49 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • BMI <30
  • Accepting to participate in the study and signed the written informed consent
  • Covered by a health insurance system

Exclusion Criteria:

  • Pregnant woman or risk of pregnancy
  • MRI contraindication
  • Protected adults
  • Language barrier
  • Previous or current hip pain

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: T1rho MRI
Patients included had hip cartilage MRI with acquisition of T1rho MRI sequence.
Device: Hip cartilage MRI
Hip cartilage MRI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quantification of the cartilage signal at T1rho MRI
Time Frame: Up to one month after inclusion (Visit 1)
T1rho values of total hip cartilage and for each sub-region (mean, standard deviation, histogram)
Up to one month after inclusion (Visit 1)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quantification of the cartilage signal at T1rho MRI
Time Frame: 15 (+/- 7) days after visit 1 (Visit 2)
T1rho values of total hip cartilage and for each sub-region (mean, standard deviation, histogram)
15 (+/- 7) days after visit 1 (Visit 2)
Quantification of the cartilage signal at T2 MRI
Time Frame: Up to one month after inclusion (Visit 1)
T2 values of total hip cartilage and for each sub-region (mean, standard deviation, histogram)
Up to one month after inclusion (Visit 1)
Quantification of the cartilage signal at T2 MRI
Time Frame: 15 (+/- 7) days after visit 1 (Visit 2)
T2 values of total hip cartilage and for each sub-region (mean, standard deviation, histogram)
15 (+/- 7) days after visit 1 (Visit 2)
Presence of cartilage lesions
Time Frame: Up to one month after inclusion (Visit 1)
Morphological sequence to determine focal lesions
Up to one month after inclusion (Visit 1)
Presence of cartilage lesions
Time Frame: 15 (+/- 7) days after visit 1 (Visit 2)
Morphological sequence to determine focal lesions
15 (+/- 7) days after visit 1 (Visit 2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospices Civils de Lyon

Investigators

  • Principal Investigator: Jean-Baptiste PIALAT, MD, PhD, Hospices Civils de Lyon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2015

Primary Completion (Actual)

January 1, 2016

Study Completion (Actual)

January 1, 2016

Study Registration Dates

First Submitted

May 26, 2016

First Submitted That Met QC Criteria

June 1, 2016

First Posted (Estimated)

June 7, 2016

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 20, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 69HCL14_0235

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteers

Clinical Trials on Hip cartilage MRI

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe